1. Vitamin D and lumisterol novel metabolites can inhibit SARS-CoV-2 replication machinery enzymes
- Author
-
Imtaiyaz Hassan, Radomir M. Slominski, Andrzej Slominski, Shariq Qayyum, Taj Mohammad, Robert C. Tuckey, and Chander Raman
- Subjects
0301 basic medicine ,Lumisterol ,Vitamin ,medicine.medical_specialty ,Physiology ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,viruses ,lumisterol ,RNA-dependent RNA polymerase ,030209 endocrinology & metabolism ,vitamin D metabolites ,Virus Replication ,Antiviral Agents ,vitamin D deficiency ,03 medical and health sciences ,chemistry.chemical_compound ,SARS-CoV-2 main protease ,0302 clinical medicine ,Physiology (medical) ,Internal medicine ,Ergosterol ,medicine ,Vitamin D and neurology ,Vitamin D ,chemistry.chemical_classification ,Protease ,Rapid Report ,SARS-CoV-2 ,COVID-19 ,medicine.disease ,RNA-Dependent RNA Polymerase ,Molecular Docking Simulation ,030104 developmental biology ,Enzyme ,Endocrinology ,chemistry ,Biochemistry - Abstract
Vitamin D deficiency significantly correlates with the severity of SARS-CoV-2 infection. Molecular docking-based virtual screening studies predict that novel vitamin D and related lumisterol hydroxymetabolites are able to bind to the active sites of two SARS-CoV-2 transcription machinery enzymes with high affinity. These enzymes are the main protease (Mpro) and RNA-dependent RNA polymerase (RdRP), which play important roles in viral replication and establishing infection. Based on predicted binding affinities and specific interactions, we identified 10 vitamin D3 (D3) and lumisterol (L3) analogs as likely binding partners of SARS-CoV-2 Mpro and RdRP and, therefore, tested their ability to inhibit these enzymes. Activity measurements demonstrated that 25(OH)L3, 24(OH)L3, and 20(OH)7DHC are the most effective of the hydroxymetabolites tested at inhibiting the activity of SARS-CoV-2 Mpro causing 10%–19% inhibition. These same derivatives as well as other hydroxylumisterols and hydroxyvitamin D3 metabolites inhibited RdRP by 50%–60%. Thus, inhibition of these enzymes by vitamin D and lumisterol metabolites may provide a novel approach to hindering the SARS-CoV-2 infection. NEW & NOTEWORTHY Active forms of vitamin D and lumisterol can inhibit SARS-CoV-2 replication machinery enzymes, which indicates that novel vitamin D and lumisterol metabolites are candidates for antiviral drug research.
- Published
- 2021